Bank of America Corp DE Acquires 731,962 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Bank of America Corp DE lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 1,165.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 794,761 shares of the company's stock after purchasing an additional 731,962 shares during the quarter. Bank of America Corp DE owned about 1.51% of Janux Therapeutics worth $42,552,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its stake in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after acquiring an additional 144,883 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock valued at $937,000 after buying an additional 7,442 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the fourth quarter valued at about $139,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after buying an additional 1,095 shares during the last quarter. Finally, Chicago Capital LLC purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth about $230,000. Institutional investors own 75.39% of the company's stock.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the business's stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders sold 10,001 shares of company stock valued at $313,964. Company insiders own 8.10% of the company's stock.

Janux Therapeutics Stock Performance

Shares of JANX traded down $0.20 on Tuesday, hitting $23.97. 124,355 shares of the stock traded hands, compared to its average volume of 865,818. The company has a market capitalization of $1.42 billion, a PE ratio of -20.44 and a beta of 3.24. The business has a 50 day simple moving average of $28.50 and a 200 day simple moving average of $40.33. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on JANX shares. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Scotiabank lowered their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.